ARGX
argenx SE
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+20/100
Last price
934.25
▲ 21.38 (2.34%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
930.99
Prev close
912.87
Day high
942.19
Day low
909.95
Volume
430.06K
Market cap
$57.87B
P/E (TTM)
34.80
52W range
661.85 – 1,072.75
Day trading desk
Gap from prior close
+1.98%
Prior close 912.87
VWAP
929.09
+0.56% from price
Relative volume
1.48×
Normal
Session range
3.54%
909.95 – 942.19
Position in range
75%
Near session high
ATR (14D)
22.49
2.41% of price
Prior day high
923.31
PDH
Prior day low
903.50
PDL
Bid / ask spread
—
Quote not published
Session volume
415.67K
Avg 280.87K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.14%
-6.1%
1M
-9.93%
-11.1%
3M
+1.66%
-2.9%
6M
+21.57%
+3.4%
YTD
+10.65%
-3.6%
1Y
+16.32%
-0.1%
3Y
+89.27%
+7.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ARGX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$57.87B
Enterprise value$1.45T
Revenue (TTM)$5.32B
Gross profit$3.14B
EBITDA$1.61B
Net income$1.72B
EPS (TTM)$26.74
Free cash flow$761.77M
Total cash$5.18B
Total debt$47.00M
Book value / share$5.38
Shares outstanding62.19M
Float1.56B
Short % of float2.10%
Dividend yield0.00%
Beta (5Y)-0.04
Valuation & profitability ratios
Trailing P/E34.80
Forward P/E26.80
PEG ratio1.12
Price / sales—
Price / book172.84
EV / revenue272.73
EV / EBITDA898.80
Gross margin59.07%
Operating margin31.99%
Profit margin32.27%
Return on equity23.64%
Return on assets11.63%
Debt / equity0.56
Current ratio5.12
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.15B | $2.19B | $1.23B | $410.75M | +89.6% |
| Operating revenue | $4.15B | $2.19B | $1.19B | $410.75M | +89.9% |
| Cost of revenue | $450.67M | $227.29M | $117.83M | $29.43M | +98.3% |
| Gross profit | $3.70B | $1.96B | $1.11B | $381.31M | +88.6% |
| Research & development | $1.36B | $983.42M | $859.49M | $663.37M | +38.7% |
| Selling, general & admin | $1.36B | $1.05B | $709.54M | $469.92M | +29.3% |
| Total operating expense | $2.65B | $1.98B | $1.53B | $1.11B | +33.7% |
| Operating income | $1.05B | -$17.84M | -$420.64M | -$723.92M | +6,010.2% |
| Net interest income | $159.01M | $155.04M | $106.48M | $22.55M | +2.6% |
| Pre-tax income | $1.28B | $85.18M | -$304.50M | -$729.31M | +1,401.1% |
| Tax provision | -$13.43M | -$747.86M | -$9.44M | -$19.72M | +98.2% |
| Net income | $1.29B | $833.04M | -$295.05M | -$709.59M | +55.1% |
| Net income to common | $1.29B | $833.04M | -$295.05M | -$709.59M | +55.1% |
| Basic EPS | 21.08 | 13.92 | -5.16 | -13.05 | +51.4% |
| Diluted EPS | 19.57 | 12.78 | -5.16 | -13.05 | +53.1% |
| EBIT | $1.28B | $87.64M | -$303.59M | -$727.12M | +1,363.5% |
| EBITDA | $1.31B | $105.17M | -$192.28M | -$622.78M | +1,146.3% |
| Basic shares | 61.30M | 59.86M | 57.17M | 54.38M | +2.4% |
| Diluted shares | 66.03M | 65.18M | 57.17M | 54.38M | +1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.49B | $1.50B | $2.05B | $800.74M | +132.8% |
| Cash & short-term investments | $4.44B | $3.38B | $3.18B | $2.19B | +31.4% |
| Accounts receivable | $1.49B | $817.71M | $417.99M | $241.23M | +82.2% |
| Inventory | $473.53M | $407.23M | $310.55M | $228.35M | +16.3% |
| Total current assets | $6.90B | $4.88B | $4.12B | $2.77B | +41.3% |
| Property, plant & equipment | $48.25M | $43.52M | $22.68M | $16.23M | +10.9% |
| Goodwill & intangibles | $272.10M | $181.44M | $125.23M | $174.90M | +50.0% |
| Total assets | $8.68B | $6.20B | $4.54B | $3.13B | +40.0% |
| Total current liabilities | $1.32B | $669.92M | $422.99M | $302.28M | +97.1% |
| Total debt | $47.16M | $39.05M | $20.00M | $12.43M | +20.8% |
| Total liabilities | $1.36B | $704.24M | $444.95M | $320.56M | +93.1% |
| Retained earnings | -$279.77M | -$1.57B | -$2.40B | -$2.11B | +82.2% |
| Shareholder equity | $7.32B | $5.50B | $4.10B | $2.81B | +33.2% |
| Working capital | $5.58B | $4.21B | $3.70B | $2.47B | +32.4% |
| Net tangible assets | $7.05B | $5.32B | $3.97B | $2.64B | +32.6% |
| Shares issued | 61.88M | 60.76M | 59.19M | 55.40M | +1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.05B | -$21.65M | -$425.05M | -$720.34M | +4,966.6% |
| Depreciation & amortisation | $28.10M | $17.53M | $111.31M | $104.34M | +60.3% |
| Stock-based compensation | $248.08M | $235.18M | $232.97M | $157.03M | +5.5% |
| Change in working capital | -$422.63M | -$325.17M | -$308.89M | -$375.72M | -30.0% |
| Operating cash flow | $685.19M | -$82.75M | -$420.33M | -$862.81M | +928.1% |
| Capital expenditure | -$111.68M | -$68.30M | -$43.81M | -$103.82M | -63.5% |
| Investing cash flow | $984.00M | -$717.59M | $308.21M | -$461.18M | +237.1% |
| Financing cash flow | $233.01M | $279.76M | $1.34B | $843.76M | -16.7% |
| Free cash flow | $573.51M | -$151.05M | -$464.14M | -$966.63M | +479.7% |
| End cash position | $3.49B | $1.50B | $2.05B | $800.74M | +132.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.51B | $1.30B | $1.29B | $1.13B | $947.96M | — | +16.7% |
| Operating revenue | $1.51B | $1.30B | $1.29B | $1.13B | $947.96M | — | +16.7% |
| Cost of revenue | $145.00M | $121.00M | $149.69M | $109.43M | $110.75M | — | +19.8% |
| Gross profit | $1.37B | $1.18B | $1.14B | $1.02B | $837.21M | — | +16.4% |
| Research & development | $486.00M | $443.00M | $371.71M | $355.65M | $327.70M | — | +9.7% |
| Selling, general & admin | $411.00M | $355.00M | $422.54M | $336.29M | $321.35M | — | +15.8% |
| Total operating expense | $876.00M | $783.00M | $778.63M | $667.57M | $633.37M | — | +11.9% |
| Operating income | $494.00M | $394.00M | $359.56M | $349.97M | $203.84M | — | +25.4% |
| Net interest income | $47.00M | $43.00M | $44.05M | $41.71M | $37.27M | — | +9.3% |
| Pre-tax income | $532.00M | $426.00M | $403.29M | $386.05M | $286.90M | — | +24.9% |
| Tax provision | $59.00M | $60.00M | -$129.66M | $41.80M | $41.54M | — | -1.7% |
| Net income | $472.00M | $366.00M | $532.95M | $344.26M | $245.36M | — | +29.0% |
| Net income to common | $472.00M | $366.00M | $532.95M | $344.26M | $245.36M | — | +29.0% |
| Basic EPS | — | 5.90 | — | 5.61 | — | 2.78 | — |
| Diluted EPS | — | 5.52 | — | 5.18 | — | 2.58 | — |
| EBIT | $533.00M | $427.00M | $404.12M | $387.05M | $288.02M | — | +24.8% |
| EBITDA | $533.00M | $427.00M | $404.12M | $387.05M | $288.02M | — | +24.8% |
| Basic shares | — | 62.06M | — | 61.37M | — | 60.98M | — |
| Diluted shares | — | 66.36M | — | 66.44M | — | 65.66M | — |
| Line item | 2026-06-30 | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $3.58B | $3.49B | $2.09B | +2.7% |
| Cash & short-term investments | $5.18B | $4.44B | $3.93B | +16.8% |
| Accounts receivable | $1.83B | $1.49B | $1.13B | +23.0% |
| Inventory | $371.00M | $473.53M | $340.62M | -21.7% |
| Total current assets | $8.07B | $6.90B | $5.83B | +16.9% |
| Property, plant & equipment | $52.00M | $48.25M | $45.80M | +7.8% |
| Goodwill & intangibles | $266.00M | $272.10M | $218.98M | -2.2% |
| Total assets | $10.03B | $8.68B | $7.18B | +15.5% |
| Total current liabilities | $1.57B | $1.32B | $1.04B | +19.3% |
| Total debt | $47.00M | $47.16M | $43.15M | -0.3% |
| Total liabilities | $1.61B | $1.36B | $1.08B | +18.8% |
| Retained earnings | $558.00M | -$279.77M | -$1.16B | +299.5% |
| Shareholder equity | $8.42B | $7.32B | $6.10B | +14.9% |
| Working capital | $6.49B | $5.58B | $4.79B | +16.4% |
| Net tangible assets | $8.15B | $7.05B | $5.88B | +15.6% |
| Shares issued | 62.54M | 61.88M | 61.20M | +1.1% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
1.22
Put-heavy session
Put / call open interest
0.44
Positioning, not flow
Max pain
900.00
-3.3% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-4.9%
Calls bid over puts
Call volume
221
Contracts, this expiry
Put volume
269
Contracts, this expiry
Heaviest call OI
920.00
268 contracts
Heaviest put OI
950.00
147 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 6.19 | 7.32 | +18.2% |
| Mar 2026 | 4.92 | 5.52 | +12.1% |
| Dec 2025 | 6.11 | 8.02 | +31.2% |
| Sep 2025 | 4.16 | 5.18 | +24.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -9.78 | 2 | $1.65B | +43.1% |
| Next quarter | 8.77 | 1 | $1.80B | +35.8% |
| Current year | 18.68 | 4 | $6.27B | +47.5% |
| Next year | 34.72 | 3 | $7.62B | +21.6% |
Analyst targets & ownership
Mean target$1,180.26
High target$1,450.00
Low target$900.00
Implied upside26.33%
Analyst count23
ConsensusBUY
Strong buy / Buy3 / 8
Hold2
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions46.07%
Institutions holding715
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
946.79
-1.32% from price
SMA 20
966.59
-3.73% from price
SMA 50
957.44
-2.81% from price
SMA 100
911.72
+2.47% from price
SMA 200
851.87
+9.23% from price
EMA 12
949.31
-1.59% from price
EMA 26
962.56
-2.94% from price
EMA 50
953.05
-1.97% from price
RSI (14)
40.7
Neutral
MACD (12,26,9)
-13.26
Hist -8.04
ATR (14)
22.49
2.42% of price
Realised vol 30D
24.7%
Annualised
Bollinger upper
1,017.26
20, 2σ
Bollinger lower
915.92
20, 2σ
50 / 200 cross
Golden
957.44 vs 851.87
Trend bias
Above 200
+9.23%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.31
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
24.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-28.6%
Peak to trough
Max drawdown 5Y
-38.2%
Peak to trough
ATR 14
22.49
2.42% of price
Beta (reported)
-0.04
5Y monthly, from filing
Short interest
Shares short
1.31M
Prior 1.20M
Change vs prior
+9.2%
Shorts adding
% of float
2.10%
Normal
% of shares out
2.10%
Against total outstanding
Days to cover
4.8
Liquid
Float
1.56B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 8, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 3, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 31, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 26, 26 | UBS | UPGRADE | Neutral | Buy |
| Aug 26, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 18, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 18, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 18, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 18, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 18, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 17, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-29
Corporate Changes & Voting Matters
6-K · 2026-08-27
Corporate Changes & Voting Matters
6-K · 2026-08-17
Tender Offer/Acquisition Reports
SC TO-T · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-08-03
Tender Offer/Acquisition Reports
SC TO-C · 2026-07-28
Corporate Changes & Voting Matters
6-K · 2026-07-27
Corporate Changes & Voting Matters
6-K · 2026-07-23
Headlines
Halozyme Expands Collaboration With argenx
MT Newswires · 6h ago
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?
Motley Fool · 2d ago
European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading
MT Newswires · 5d ago
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
MT Newswires · 7d ago
Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium
MT Newswires · 8d ago
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
Business Wire · 8d ago
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
GlobeNewswire · 8d ago
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months
Motley Fool · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.